Netherton Syndrome
A complex condition combining ichthyosis, severe allergic disease, and unique hair shaft abnormalities. Management requires a specialist allergist alongside dermatology.
Netherton Syndrome is now also classified as SPINK5-sEDD under the new gene-based EDD system. Both names remain valid.
1. Ichthyosis linearis circumflexa (scaling) 2. Trichorrhexis invaginata (bamboo hair) 3. Severe atopy (eczema, asthma, allergies)
Hair shafts have characteristic "bamboo nodes" visible under microscopy. Hair is brittle and sparse. Can also affect eyebrows and eyelashes.
Extremely high IgE. Multiple food allergies common. Anaphylaxis risk requires adrenaline auto-injector (EpiPen) in many patients.
LEKTI (the protein encoded by SPINK5) is absent. This causes uncontrolled protease activity, destroying the skin barrier from within.
- Topical corticosteroids: Increased systemic absorption due to defective skin barrier — risk of adrenal suppression. Use with extreme caution only under specialist guidance.
- NSAIDs (ibuprofen, aspirin): Can trigger anaphylaxis in sensitised individuals.
- Calcineurin inhibitors (tacrolimus, pimecrolimus): Use with significant caution — systemic absorption risk. Only under specialist guidance.
- Emollients containing common allergens: Check ingredients — peanut oil (in some emollients), oat (Aveeno) may trigger reactions.
Daily Routine
- Lukewarm bath or shower (15–20 min) — Avoid hot water. Fragrance-free bath additives only (check for allergens).
- Hypoallergenic emollient — Diprobase (fragrance-free), Cetraben, or Zeroderm. Avoid emollients with nut oils, oat, or fragrances.
- Apply dupilumab injection — If on dupilumab biologic therapy (every 2 or 4 weeks per schedule)
- Check EpiPen — Ensure adrenaline auto-injector is accessible and in date at all times
- Antihistamine — Non-sedating (cetirizine, loratadine) if daily itching/urticaria
- Food allergen avoidance — Check all food labels; follow your allergen exclusion list
- Therapeutic bath — 20–30 minutes with safe bath oil (check allergens). Oilatum Fragrance-Free or sodium bicarbonate bath.
- Emollient application — After bath, apply liberally. Wet wrapping on severe eczema areas if needed.
- Bandaging or wet wrapping if appropriate — Wet bandages over emollient can dramatically reduce overnight itch and scale. Discuss with dermatology team.
- Sedating antihistamine — Chlorphenamine (Piriton) at night if itch severely affects sleep (short-term use)
- Cotton nightwear and bedding — Organic cotton preferred; wash at 60°C to kill dust mites
Anaphylaxis preparedness
- Adrenaline auto-injector (EpiPen): Carry two at all times. Ensure school/work staff are trained in use.
- Allergy action plan: Written and laminated — copy with patient, at school, at work.
- Allergen avoidance: Work with dietitian to maintain safe diet. Medic Alert bracelet recommended.
- Allergy testing: Regular review with allergist. Allergy landscape can change over time.
- Triggers beyond food: Exercise, NSAIDs, stress can all trigger reactions in Netherton. Know your triggers.
What to do in anaphylaxis
- Administer EpiPen to outer thigh (through clothing if needed)
- Call 999 immediately
- Lie flat with legs raised (unless breathing difficult — then sit up)
- Second EpiPen after 5–15 minutes if no improvement
- Go to A&E for at least 6 hours of observation
Netherton hair is characteristically brittle due to trichorrhexis invaginata. Handle with extreme care:
- Never use harsh shampoos — fragrance-free, hypoallergenic formulas only
- No heat styling, chemical treatments, or bleaching
- Gentle scalp emollient for scaling: Capasal shampoo or coconut oil (check tolerance first)
- Use wide-tooth comb only, never brush aggressively
- Hair may improve with systemic treatment (dupilumab or retinoids)
- Hair appearance is not a measure of treatment success — focus on skin and allergy control
Medication Options
| Drug | Type | Efficacy | Evidence | Notes |
|---|---|---|---|---|
| Emollients (fragrance-free) | Emollient | 60% | Established | Must be allergen-checked. Cornerstone of care. |
| Dupilumab (Dupixent) | Biologic (anti-IL-4/IL-13) | 75–80% | Growing evidence (off-label) | Target therapy for high-IgE atopic component. Transformative for some. |
| IVIG (intravenous immunoglobulin) | Immunomodulatory | 60% | Case series | Used in severe atopy refractory to other treatments |
| Topical steroids (mild only) | Anti-inflammatory | Moderate | Use with caution | Increased absorption — brief courses only under specialist supervision |
| Acitretin | Systemic retinoid | 50–60% | Limited evidence | Less effective than in lamellar; may help ichthyosis component |
| Secukinumab, omalizumab | Biologic (research) | Emerging | Case reports | Being evaluated in refractory cases |
Common Problems & Solutions
- Dupilumab is the most promising treatment for itch in Netherton — discuss with dermatologist
- Wet wrapping: damp cotton bandages over emollient can dramatically reduce overnight itch
- Cool environment — heat massively worsens Netherton itch
- Avoid triggering foods that may be causing low-grade allergic responses
- CBT for itch (cognitive behavioural therapy) — has evidence in chronic itch conditions
- Netherton skin barrier is severely compromised — infection risk is high
- Signs of infection: weeping, crusting, warmth, fever, spreading redness — treat promptly
- Staph aureus is the most common pathogen — flucloxacillin usually first-line
- Bleach bath protocol (dilute sodium hypochlorite) can reduce staph colonisation — discuss with dermatologist first
- Rapid GP access agreement — ensure you can be seen urgently when infections develop
- School individual health care plan (IHCP) is essential — includes allergen avoidance, EpiPen training for staff, emergency protocol
- Allergy UK resources and school template letters available free
- Canteen must provide allergen information — this is legal requirement
- Work: Equality Act 2010 applies — employer must make reasonable adjustments (safe food, EpiPen access, reduced stress exposure)
Key Research — Biologics & Emerging Treatments
2024 — Journal of Clinical Immunology
Dupilumab in a 9-week-old with Netherton Syndrome Leads to Deep Symptom Control
Rapid, sustained resolution of allergic inflammation in an infant treated from 9 weeks of age. Normalisation of skin microbiome and catch-up somatic and psychomotor development. No adverse drug reactions.
2025 — BJD · Real-World Biologics Data
Biologics in congenital ichthyosis: are they effective? (98 patients)
Real-world cohort of 98 patients (mean age 19.7 yrs). Netherton syndrome was the most common type treated (30%). 46% were overall responders; 18% were good responders. Best results with IL-4R, IL-17, and IL-12/23 inhibitors in erythrodermic forms. Highlights that published case reports overstate response rates vs real-world data.
2025 — PubMed · JAK Inhibitor
Abrocitinib (JAK1 inhibitor) alleviates Netherton syndrome symptoms
Marked improvement after 6 months of oral abrocitinib (already approved for atopic eczema) in a Netherton patient. Significant reduction in skin rash and overall disease severity. Emerging as an additional oral option alongside dupilumab — particularly useful where dupilumab is unavailable or ineffective.
2025 — Journal of Dermatological Treatment
Effect on ichthyosis linearis circumflexa with dupilumab
Dupilumab 300mg/4 weeks showed >40% improvement in SCORAD, EASI, and CDLQI in a girl with SPINK5-sEDD. Eczema, itch, and hair improved significantly. Important finding: recurrent flares of ichthyosis linearis circumflexa still occurred — dupilumab controls the atopic/inflammatory component better than the ichthyotic scaling itself.
2026 — Pediatric Dermatology · Hair
Hair improvement in SPINK5-sEDD (Netherton syndrome) with dupilumab
11-year-old girl with SPINK5-sEDD showed marked, sustained improvement in hair density, texture, and pruritus on dupilumab. Proposed mechanism: IL-4/IL-13 blockade modulates the perifollicular inflammatory environment and supports follicular function — extending the benefit profile beyond skin and itch to trichorrhexis invaginata. First case to use the new SPINK5-sEDD nomenclature in the journal title.
2026 — An Bras Dermatol · Treatment Failure
Dupilumab-resistant Netherton syndrome with a novel SPINK5 variant
First documented dupilumab non-responder in Netherton syndrome — a paediatric patient with compound heterozygous SPINK5 mutations including the novel missense variant c.575A>G (p.Asn192Ser), predicted to disrupt LEKTI structural stability. Cytokine profiling showed selective IL-4 elevation in lesional skin despite normal blood levels, suggesting tissue-specific Th2 inflammation. Important counterpoint to high reported response rates — discuss variant testing with your specialist before assuming response.
Red Flags
- Anaphylaxis: throat tightening, lips swelling, difficulty breathing, collapse — GIVE EpiPen IMMEDIATELY then call 999
- Widespread skin infection with high fever and confusion (sepsis)
- Severe dehydration from skin fluid loss in infants
- Any new food or environmental allergy developing
- Skin infection that doesn't respond to first-line antibiotics within 48 hours
- If current treatment is insufficient and quality of life is severely impacted